Q-omics provides the consensus-scored TSHB profile across patient tissues and cancer cell-line models. TSHB expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TSHB is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, TSHB RNA expression shows 10,463 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, BLCA, and TGCT as cancer lineages where TSHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSHB survival associations across molecular data types. TSHB RNA expression shows survival associations in the most cancer types (17), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSHB RNA expression–survival associations across cancer types. High TSHB expression shows unfavorable associations in THCA, CESC, ACC and ESCA, but favorable associations in PAAD and KIRC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for TSHB RNA expression.
This table summarizes TSHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TSHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSHB shows lower tumor expression in BLCA, THCA, KIRP, COAD, KIRC and KICH. The BLCA box plot shows higher TSHB RNA expression in normal versus tumor tissue (log2 FC = −1.104, t-test p < 0.001).
This table shows molecular features associated with TSHB in patient tissues and cancer cell lines. In patient samples, TSHB shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TSHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
